Bone Biologics Receives Approval

Bone Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX®) in Australia

See Full Article...

UCLA TDG is happy to share that Bone Biologics, UCLA TDG’s licensee receives Human Research Ethics Committee (HREC) approval for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX®) in Australia. This product stems from a UCLA research led by Dr. Chia Soo., Dr. Kang Ting and Dr. Ben Woo and was Licensed from UCLA TDG.